LONDON – The Bill and Melinda Gates Foundation is to invest $40 million in Immunocore Ltd., in a move that will take the company's T-cell receptor platform beyond the current focus in cancer and into the treatment of infectious diseases, and in particular HIV and tuberculosis (TB).